| Literature DB >> 31173929 |
Jamie L Duke1, Timothy L Mosbruger1, Deborah Ferriola1, Nilesh Chitnis1, Taishan Hu1, Nikolaos Tairis1, David J Margolis2, Dimitri S Monos3.
Abstract
The technical limitations of current next-generation sequencing technologies, combined with an ever-increasing number of human leukocyte antigen (HLA) alleles, form the basis for the additional ambiguities encountered at an increasing rate in clinical practice. HLA-DPB1 characterization, particularly, generates a significant percentage of ambiguities (25.5%), posing a challenge for accurate and unambiguous HLA-DPB1 genotyping. Phasing of exonic heterozygous positions between exon 2 and all other downstream exons has been the major cause of ambiguities. In this study, the Oxford Nanopore MinION, a third-generation sequencing technology, was used to resolve the phasing. The accurate MiSeq sequencing data, combined with the long reads obtained from the MinION platform, allow for the resolution of the tested ambiguities.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31173929 PMCID: PMC6734860 DOI: 10.1016/j.jmoldx.2019.04.009
Source DB: PubMed Journal: J Mol Diagn ISSN: 1525-1578 Impact factor: 5.568